Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
3.120
-0.120 (-3.70%)
At close: Sep 2, 2025, 4:00 PM
3.150
+0.030 (0.96%)
After-hours: Sep 2, 2025, 7:56 PM EDT
Prime Medicine Employees
Prime Medicine had 214 employees as of December 31, 2024. The number of employees decreased by 20 or -8.55% compared to the previous year.
Employees
214
Change (1Y)
-20
Growth (1Y)
-8.55%
Revenue / Employee
$23,182
Profits / Employee
-$931,192
Market Cap
409.04M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 214 | -20 | -8.55% |
| Dec 31, 2023 | 234 | 59 | 33.71% |
| Dec 31, 2022 | 175 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PRME News
- 7 days ago - Prime Medicine to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 26 days ago - Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 4 weeks ago - Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 4 weeks ago - Prime Medicine Announces Pricing of Public Offering - GlobeNewsWire
- 4 weeks ago - Prime Medicine Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 6 weeks ago - Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy - Business Wire
- 6 weeks ago - Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis - GlobeNewsWire
- 2 months ago - Prime Medicine: Pressing Forward With Lead Liver Targeting Indications - Seeking Alpha